Trevi Therapeutics (TRVI) Q4 2025 earnings review
Transitioning to Late-Stage Execution With a Full War Chest
Trevi Therapeutics is officially a late-stage clinical company. Following successful End-of-Phase 2 FDA meetings, the company is preparing to launch a massive clinical program in 2026 for its lead asset, Haduvio. The Q4 financial results reflect a temporary optical illusion: Net Loss decreased 27% YoY to $8.3M, driven by a lull in R&D spending between the completion of Phase 2 trials and the initiation of Phase 3. However, with a $188.3M cash balance, the company is well-capitalized to handle the impending expense acceleration as it initiates four major trials in the coming quarters.
🐂 Bull Case
FDA alignment on the Phase 3 program for Idiopathic Pulmonary Fibrosis (IPF) related chronic cough removes a major overhang. Initiating two pivotal trials in 2026 sets a concrete timeline to an NDA.
The $188.3M cash position provides a runway into 2028, ensuring Trevi can fund its ambitious slate of clinical trials without needing highly dilutive near-term capital raises.
🐻 Bear Case
Initiating two Phase 3 trials and two Phase 2b trials simultaneously in 2026 presents a severe operational bottleneck. Any delays in site activation or enrollment will push back the 2028 cash runway limits.
The Q4 drop in R&D spending is a head fake. Launching parallel global pivotal trials will cause cash burn to accelerate violently from the current ~$10M/quarter pace.
⚖️ Verdict: ⚪
Neutral/Cautiously Optimistic. The clinical path is de-risked and the balance sheet is fortified. However, the sheer operational weight of running four late-stage global clinical trials simultaneously will test management's execution capabilities over the next 18 months.
Key Themes
Phase 3 IPF Cough Program Cleared for Launch
Following an End-of-Phase 2 meeting, Trevi secured FDA alignment for two parallel Phase 3 trials in IPF-related chronic cough. The first trial (300 patients, 52-week dosing) initiates in Q2 2026; the second (130 patients, 12-week dosing) initiates in H2 2026. This transitions Trevi into a pivotal-stage company targeting an indication with ~150,000 U.S. patients and zero FDA-approved therapies.
Addressable Market Expansion via RCC and non-IPF ILD
Management is aggressively expanding the pipeline to target broader markets. A Phase 2b trial for Refractory Chronic Cough (RCC)—a 2-3 million U.S. patient market—initiates in Q2 2026. Additionally, an adaptive Phase 2b trial for non-IPF Interstitial Lung Disease (non-IPF ILD) initiates in H2 2026, targeting an additional 228,000 U.S. patients. This effectively multiplies Haduvio's total addressable market.
Differentiated KAMA Dual Mechanism
Haduvio's specific technology—acting as both a kappa agonist and a mu antagonist (KAMA)—targets the cough reflex arc both centrally and peripherally. This dual-action mechanism is a key clinical differentiator compared to purely peripheral-acting competitors (like P2X3 antagonists), having demonstrated statistically significant reductions in cough frequency in earlier Phase 2a (RIVER) and Phase 2b (CORAL) trials.
The Q4 R&D Expense 'Lull' Will Violently Reverse
Q4 2025 R&D expenses plummeted 33% YoY to $6.2M, driving a lower overall net loss. This data point falsely suggests improving operational efficiency; in reality, it merely reflects the gap between the completion of Phase 2 enrollment and the costly initiation of Phase 3. With four trials launching in 2026, operating expenses are guaranteed to accelerate sharply, stress-testing the company's burn rate projections.
Macro Regulatory Backdrop: Opioid Class Scrutiny
Because Haduvio acts on opioid receptors, the macro regulatory environment remains a hurdle. While unscheduled by the DEA, the FDA's intense scrutiny of opioid-related respiratory profiles means the requirement for robust 52-week safety data in the Phase 3 program is a non-negotiable, expensive, and time-consuming prerequisite for any future NDA submission.
Creeping G&A Expenses
While R&D temporarily decelerated, G&A expenses accelerated 38% YoY in Q4 to $4.0M (up from $2.9M). For the full year, G&A jumped 31% to $15.9M. Management attributes this to personnel and professional fees. If administrative bloat outpaces trial execution, it will erode the 2028 cash runway.
Other KPIs
Decelerating. Down 33% from $9.3M in Q4 2024. The reduction is solely due to the completion of enrollment in the Phase 2a RIVER and Phase 2b CORAL trials. Investors should model a steep re-acceleration starting in Q2 2026 as pivotal trials commence.
Stable/Improving vs FY24 ($47.9M). This ~11% improvement in net loss was aided by a $2.9M increase in interest income (Other Income, net) due to higher yields on the company's boosted cash balance following its mid-2025 capital raise.
Guidance
Stable. The company explicitly reaffirmed that its $188.3M in cash and marketable securities will fund operations into 2028. This implies an average annual burn rate of roughly $60M-$70M over the next 2-3 years, a significant acceleration from the $42.8M burned in 2025.
Accelerating from planning to execution. This is the 300-patient, 52-week fixed dosing trial. Meeting this timeline is critical for maintaining investor confidence.
Accelerating pipeline breadth. Will measure mean change in 24-hour cough frequency using objective monitors.
The companion pivotal trial (130 patients, 12-week dosing) slated for the back half of the year, staggering the operational load slightly from the Q2 trial launches.
Key Questions
2026 Cash Burn Trajectory
With R&D falling to $6.2M in Q4, but four new mid-to-late stage trials initiating in 2026, what is the expected peak quarterly cash burn rate once all trials are actively enrolling?
Phase 3 Enrollment Feasibility
Running two Phase 3 IPF trials and a Phase 2b non-IPF ILD trial concurrently means intense competition for pulmonary trial sites and patients. How is the company mitigating enrollment cannibalization across its own pipeline?
Safety Database Requirements
The FDA requires 52-week safety data. Will the 300-patient Phase 3 IPF trial be sufficient on its own to hit the FDA's total exposure numbers for an NDA, or will additional open-label extension cohorts be required?